120 related articles for article (PubMed ID: 29678834)
1. From Pluripotent Stem to CAR T Cells.
Cancer Discov; 2018 Jun; 8(6):OF5. PubMed ID: 29678834
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
3. Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review.
Vonk LA; de Windt TS; Slaper-Cortenbach IC; Saris DB
Stem Cell Res Ther; 2015 May; 6(1):94. PubMed ID: 25976213
[TBL] [Abstract][Full Text] [Related]
4. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Torikai H; Cooper LJ
Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
7. New cell sources for T cell engineering and adoptive immunotherapy.
Themeli M; Rivière I; Sadelain M
Cell Stem Cell; 2015 Apr; 16(4):357-66. PubMed ID: 25842976
[TBL] [Abstract][Full Text] [Related]
8. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
9. [Immune cells derived from induced pluripotent stem cells: a new cell source for cancer immunotherapy].
Ueda N; Kaneko S
Nihon Rinsho; 2017 Feb; 75(2):317-322. PubMed ID: 30562871
[TBL] [Abstract][Full Text] [Related]
10. NKT cells - New players in CAR cell immunotherapy?
Kriegsmann K; Kriegsmann M; von Bergwelt-Baildon M; Cremer M; Witzens-Harig M
Eur J Haematol; 2018 Dec; 101(6):750-757. PubMed ID: 30187578
[TBL] [Abstract][Full Text] [Related]
11. [Pluripotent stem cells as a source for T cell research and clinical application].
Ueda T; Kaneko S
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(2):101-8. PubMed ID: 26016637
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
14. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
15. An Update on the Therapeutic Potential of Stem Cells.
Rameshwar P; Moore CA; Shah NN; Smith CP
Methods Mol Biol; 2018; 1842():3-27. PubMed ID: 30196398
[TBL] [Abstract][Full Text] [Related]
16. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?
Hombach AA; Abken H
Expert Rev Clin Immunol; 2017 Feb; 13(2):151-155. PubMed ID: 27546707
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic CAR-T Cells: More than Ease of Access?
Graham C; Jozwik A; Pepper A; Benjamin R
Cells; 2018 Oct; 7(10):. PubMed ID: 30275435
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
19. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
Ebert LM; Yu W; Gargett T; Brown MP
Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
[TBL] [Abstract][Full Text] [Related]
20. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
